Ipratropium/Salbutamol Sandoz

Ipratropium bromide and Salbutamol, the active ingredients in Ipratropium/Salbutamol Sandoz, are a combination bronchodilator presented as an inhalation solution for nebulisation use. The product provides rapid bronchodilation for the management of asthma and chronic obstructive pulmonary disease (COPD) in adult patients.

GNH USA supplies Ipratropium/Salbutamol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, complying with EU regulatory standards.

Ipratropium/Salbutamol Sandoz is a combination bronchodilator used in the respiratory disease pathway to relieve bronchospasm.

Asthma: improves airflow and relieves bronchospasm in acute and chronic asthma management. COPD: reduces airway resistance and improves breathing in chronic obstructive pulmonary disease. Exercise‑induced bronchospasm: provides rapid relief of bronchoconstriction triggered by physical activity.

Ipratropium/Salbutamol Sandoz may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Tremor - Headache - Dry mouth - Cough or throat irritation - Nausea - Dizziness

Serious or Rare Side Effects: - Paradoxical bronchospasm - Tachycardia or arrhythmia - Angioedema or severe allergic reaction - Hyperglycaemia - Severe hypotension - Respiratory distress requiring medical attention

Before prescribing Ipratropium/Salbutamol Sandoz, consider the following precautions.

Monitor cardiac status: patients with known heart disease should be observed for tachyarrhythmias. Assess respiratory technique: ensure correct nebuliser use to avoid inadequate dosing. Avoid overuse: limit frequency according to prescriber instructions. Pregnancy safety: use only if the potential benefit outweighs the potential risk. Renal impairment: adjust dose and monitor renal function as needed. Store at room temperature: keep in the original container, protect from light and moisture.

Ipratropium/Salbutamol Sandoz can interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Non‑selective beta‑blockers (may diminish bronchodilation) - MAO inhibitors (risk of hypertensive crisis) - Tricyclic antidepressants (enhanced cardiovascular effects)

Moderate Interactions (Monitor Closely): - Diuretics (potential hypokalaemia) - Theophylline (increased risk of tachycardia) - ACE inhibitors (possible additive cough) - Other β2‑agonists (risk of cumulative tachycardia)